Table 1.
Subject | Age | Gender |
Baseline BCVA |
CMT | Lens | Visual symptoms | ||
---|---|---|---|---|---|---|---|---|
Snellen | Letters | Decimal | ||||||
1 | 73 | Female | 20/63 | 26 | 0.32 | 286 | Pseudoaphakic | Blurred vision and metamorphopsia |
2 | 71 | Female | 20/63 | 28 | 0.32 | 269 | Phakic | Metamorphopsia |
3 | 67 | Male | 20/50 | 33 | 0.4 | 315 | Phakic | Blurred vision and metamorphopsia |
4 | 65 | Female | 20/32 | 42 | 0.63 | 273 | Phakic | Metamorphopsia |
5 | 70 | Male | 20/40 | 37 | 0.5 | 266 | Pseudoaphakic | Blurred vision and metamorphopsia |
6 | 68 | Female | 20/100 | 19 | 0.2 | 318 | Phakic | Blurred vision and metamorphopsia |
Abbreviations: BCVA, best-corrected visual acuity; CMT, central subfield thickness.